Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

If your rapid COVID-19 tests have reached their expiration dates, don't toss them just yet. Here's how to find out if their ...

Researchers at Kumamoto University have made a significant breakthrough in the fight against COVID-19 with the development of ...

Goldman Sachs upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $137, up from $90. The firm upgrade the shares after ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

COVID-19 spreads from an infected person to others through respiratory droplets and aerosols that can vary in size, such as: large droplets that fall to the ground rapidly (within seconds or minutes) ...

New research is providing a more precise prediction of COVID-19 severity that can be found by looking at autoantibodies in the nasal cavity, leading to more personalized treatment plans.

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

A wide variety of COVID-19 symptoms exist, ranging from mild to severe, and while current strains of the virus generally cause milder symptoms, those with co-morbidities are still at an exponentially ...